{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/9ab80af0\"></iframe>","width":"100%","height":180,"duration":616,"description":"Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases patients' risk for many kinds of cancer.\nSpeaker 3: (00:32)\nCould you provide our listeners with a little bit about yourself and your background?\n \nSpeaker 3: (01:27)\n Could you give an overview of our MLH1 hypermethylation, also referred to as MLHPB in our test catalog? \n \nSpeaker 3: (02:48)\n Can you talk about why your team thought it was really important to develop this test?\n \nSpeaker 3: (04:03)\n What patients would this testing really benefit?\n \nSpeaker 3: (06:10)\nHow are the results used in patient care?\n \nSpeaker 3: (07:56)\n Anything else you would like our listeners to hear about MLHPB?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}